| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3554 | 2014 |
| Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy N Hanna, FA Shepherd, FV Fossella, JR Pereira, F De Marinis, ... Journal of clinical oncology 22 (9), 1589-1597, 2004 | 3387 | 2004 |
| Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC C Waldherr, M Pless, HR Maecke, T Schumacher, A Crazzolara, ... Journal of Nuclear Medicine 43 (5), 610-616, 2002 | 624 | 2002 |
| Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a … DC Betticher, SF Hsu Schmitz, M Tötsch, E Hansen, C Joss, C Von Briel, ... Journal of Clinical oncology 21 (9), 1752-1759, 2003 | 519 | 2003 |
| The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study C Waldherr, M Pless, HR Maecke, A Haldemann, J Mueller-Brand Annals of Oncology 12 (7), 941-945, 2001 | 509 | 2001 |
| Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial M Pless, R Stupp, HB Ris, RA Stahel, W Weder, S Thierstein, MA Gerard, ... The Lancet 386 (9998), 1049-1056, 2015 | 385 | 2015 |
| Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, ... Annals of Oncology 27 (2), 281-286, 2016 | 317 | 2016 |
| Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study DC Betticher, SF Hsu Schmitz, M Tötsch, E Hansen, C Joss, C Von Briel, ... British journal of cancer 94 (8), 1099-1106, 2006 | 243 | 2006 |
| A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer R Ramlau, E Quoix, J Rolski, M Pless, H Lena, E Lévy, M Krzakowski, ... Journal of Thoracic Oncology 3 (7), 735-744, 2008 | 233 | 2008 |
| Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial R Rosell, U Dafni, E Felip, A Curioni-Fontecedro, O Gautschi, S Peters, ... The Lancet Respiratory Medicine 5 (5), 435-444, 2017 | 214 | 2017 |
| Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer C Rochlitz, R Figlin, P Squiban, M Salzberg, M Pless, R Herrmann, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2003 | 206 | 2003 |
| SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non–small-cell lung cancer—a multicenter single-arm phase II trial SI Rothschild, A Zippelius, EI Eboulet, S Savic Prince, D Betticher, ... Journal of clinical oncology 39 (26), 2872-2880, 2021 | 199 | 2021 |
| Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions AH Diacon, C Wyser, CT Bolliger, M Tamm, M Pless, AP Perruchoud, ... American journal of respiratory and critical care medicine 162 (4), 1445-1449, 2000 | 193 | 2000 |
| Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 … C Mamot, D Klingbiel, F Hitz, C Renner, T Pabst, C Driessen, U Mey, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 184 | 2015 |
| Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS … S Peters, E Felip, U Dafni, C Belka, M Guckenberger, A Irigoyen, E Nadal, ... Lung cancer 133, 83-87, 2019 | 153 | 2019 |
| Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients … A Papachristofilou, MM Hipp, U Klinkhardt, M Früh, M Sebastian, C Weiss, ... Journal for immunotherapy of cancer 7, 1-14, 2019 | 148 | 2019 |
| Effects of nutrition and physical exercise intervention in palliative cancer patients: a randomized controlled trial A Uster, M Ruehlin, S Mey, D Gisi, R Knols, R Imoberdorf, M Pless, ... Clinical nutrition 37 (4), 1202-1209, 2018 | 147 | 2018 |
| Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial AJ de Langen, ML Johnson, J Mazieres, AMC Dingemans, G Mountzios, ... The Lancet 401 (10378), 733-746, 2023 | 139 | 2023 |
| Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial … T Ruhstaller, M Pless, D Dietrich, H Kranzbuehler, R von Moos, ... Journal of clinical oncology 29 (6), 626-631, 2011 | 133 | 2011 |
| Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 … S Kubicka, R Greil, T André, J Bennouna, J Sastre, E Van Cutsem, ... Annals of oncology 24 (9), 2342-2349, 2013 | 127 | 2013 |
Bernard Mathey-PrevotProfessor in Pediatrics, Duke University Medical CenterVerified email at dm.duke.edu
